The CANDELA Study-Trends and End Points

Chirag Jhaveri^{1

2}

Affiliations

Comment

Chirag Jhaveri. JAMA Ophthalmol. 2023.

. 2023 Sep 1;141(9):843.

doi: 10.1001/jamaophthalmol.2023.2864.

Chirag Jhaveri^{1

2}

Erratum in

Error in Text.
[No authors listed] [No authors listed] JAMA Ophthalmol. 2024 Jan 1;142(1):78. doi: 10.1001/jamaophthalmol.2023.5822. JAMA Ophthalmol. 2024. PMID: 38060248 Free PMC article. No abstract available.

No abstract available

Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, Abraham P, Fein JG, Chu KW, Clark WL, Leal S, Schmelter T, Hirshberg B, Yancopoulos GD, Vitti R; CANDELA Study Investigators. Wykoff CC, et al. JAMA Ophthalmol. 2023 Sep 1;141(9):834-842. doi: 10.1001/jamaophthalmol.2023.2421. JAMA Ophthalmol. 2023. PMID: 37535382 Free PMC article.